Pipeline has reached clinical and regulatory maturity following recent alignment with FDA on Phase 3 development pathway for CAD-1005Cadrenal has received strong interest from potential strategic partnersCadrenal will
PONTE VEDRA, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan
PONTE VEDRA, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan
FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S. and an Estimated
PONTE VEDRA, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan
Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes of cardio-renal
Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditionsCompany is exploring development, licensing, and commercialization
Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in more than a
$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027; if
Selection highlights the clinical value potential of Cadrenal’s first-in-class 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT) First-ever randomized, blinded, placebo-controlled trial in HIT, a
Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to global pharmaceutical partners at the 2026 BIO International Convention in San Diego Kawasaki disease is the leading
New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussionsAdditional billion-dollar target- Cardiac Surgery-Associated Acute Kidney Injury
Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential 12-LOX could play a central
PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions,
PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions,
